- Fosun Pharma reported a net income of 821.3 million yuan for the third quarter.
- The company’s revenue for the same period was 9.88 billion yuan.
- Earnings per share (EPS) for the third quarter stood at 31 RMB cents.
- For the first nine months, Fosun Pharma’s net income totaled 2.52 billion yuan.
- Market analysts have given Fosun Pharma 6 buy ratings, 2 hold ratings, and 0 sell ratings.
A look at Shanghai Fosun Pharmaceutical (Group) Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a pharmaceutical company with a diverse portfolio, boasts promising long-term prospects based on the Smartkarma Smart Scores. With strong scores in value, dividend, and momentum, the company is positioned well for future growth. The company’s focus on genetic medicines, traditional Chinese medicines, and diagnostic products, coupled with its investment in trading and services, reflects a robust and well-rounded business model.
The Smartkarma Smart Scores reveal Shanghai Fosun Pharmaceutical’s (Group) solid performance in key areas like value, dividend, and momentum, indicating a favorable long-term outlook. While growth and resilience scores are slightly lower, the company’s strategic investments and broad range of offerings provide a foundation for continued success in the competitive pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
